What is Nucleus Genomics?
Founded in 2021 and headquartered in New York, NY, Nucleus Genomics operates at the intersection of biotechnology and consumer technology. The company provides a platform for genetic testing and in-depth analysis, aiming to empower individuals with actionable insights into their health, ancestry, and predispositions. By leveraging advanced genomic sequencing and data analytics, Nucleus Genomics seeks to democratize access to genetic information, enabling personalized health and wellness decisions. The company's focus on consumer-facing applications positions it within a rapidly expanding market driven by increasing awareness of genetic predispositions and the desire for tailored health solutions.
How much funding has Nucleus Genomics raised?
Nucleus Genomics has raised a total of $31.5M across 3 funding rounds:
Angel/Seed
$3.5M
Unspecified
$14M
Series A
$14M
Angel/Seed (2021): $3.5M, investors not publicly disclosed
Unspecified (2022): $14M led by Seven Seven Six
Series A (2025): $14M supported by Seven Seven Six and Founders Fund
Key Investors in Nucleus Genomics
Seven Seven Six
Seven Seven Six is an early-stage venture capital firm focused on innovation at the intersection of product and people. They utilize a proprietary operating system to enhance team scalability and portfolio monitoring, aiming to empower startups with capital and operational support.
Founders Fund
Founders Fund invests in significant companies across all sectors and stages, with partners having a history of founding and funding major tech companies. They offer a founder-friendly investment strategy with substantial support and minimal interference.
What's next for Nucleus Genomics?
The substantial enterprise-level funding, including the recent strategic investment, positions Nucleus Genomics for accelerated expansion and product development. This capital infusion is expected to fuel advancements in their analytical capabilities, enhance their platform's user experience, and broaden their market reach. Strategic partnerships and further research into genetic markers are likely next steps, aiming to solidify their competitive advantage. The company's trajectory suggests a move towards scaling operations and potentially exploring new verticals within the personalized health and diagnostics sector, building upon its foundation in consumer genetic analysis.
See full Nucleus Genomics company page
